Clinical Trial Update: A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial evaluating ABT-894 for efficacy in adults with Attention-Deficit/Hyperactivity Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• ABT-894 (ABT-894)

Snippet

Sponsor: Abbott | Conditions: Attention-Deficit/Hyperactivity Disorder, ADHD | Phase 2 | Status: COMPLETED